Novartis buys Chiron
This article was originally published in The Gray Sheet
Executive Summary
Novartis enters definitive agreement with Chiron Oct. 31 to buy the remaining 58% of the company for $45 a share, or about $5.1 bil. in cash. The deal is subject to approval of Chiron's shareholders, other than Novartis, and is expected to close in early 2006. In August, Chiron's board of directors rejected a buyout offer from Novartis of $40 per share ($4.5 bil.) (1"The Gray Sheet" Sept. 12, 2005, In Brief). On Nov. 3, Novartis announced its intention to appoint its current Global Head of Pharma Development Joerg Reinhardt, PhD, to head-up the new diagnostics and vaccines division that will be created from Chiron business units...
You may also be interested in...
Chiron deal cleared
European Commission approves Novartis' $5.1 bil. acquisition of blood-test and vaccine producer Chiron, passing the deal into the hands of shareholders. In the U.S., FTC cleared the deal at the end of 2005. Chiron anticipates that the acquisition will be completed before the end of the second quarter. Chiron and Novartis began moving toward a merger in September 2005 (1"The Gray Sheet" Nov. 7, 2005, In Brief)...
Chiron Rejects Novartis’ Offer
Chiron's board of directors has rejected Novartis' Aug. 31 offer to buy the remaining 58% of Chiron, the firm announced Sept. 5. Novartis' offer of $4.5 bil. ($40.00 per share) is "inadequate," according to Chiron's board. Chiron's stock jumped 18% from $36.44 on Aug. 31 to $42.93 on Sept. 1 and closed $42.79 on Sept. 5. Novartis bought 42% of Chiron in 1995. "Over the 10 years since Novartis has been Chiron's largest stockholder, Chiron has regularly discussed with Novartis a number of strategic initiatives," Chiron states in a release. "As a result, Chiron has had an on-going dialogue with Novartis regarding its intentions with respect to its investment in Chiron. The firm's independent directors have not, however, solicited an offer to buy Chiron." Chiron manufactures blood-testing products, including the Procleix nucleic acid testing system (1"The Gray Sheet" Sept. 5, 2005, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”